Knowledge of the mechanisms of action of this disease, a disease that is diagnosed in more than 1,000 new patients each year, will, according to scientists who have participated in the discovery, design therapies.

Spanish researchers have sequenced the complete genome of cells of four patients with this cancer. This will take a big step in the treatment of the disease, while awake new expectations with regard to combating the disease-causing mutations.

The study, published in Nature, is led by a researcher at the Hospital Clinic of Barcelona and Elias Campo scientist at the University of Oviedo Carlos Lopez Otin. The two experts, along with the Science Minister, Cristina Garmendia, explained yesterday the finding, which is the first Spanish contribution to the International Consortium Cancer Genome (ICGC). And, as noted Otín, "will develop therapeutic strategies aimed specifically at the mutations that underlie the disease"
The sponsors of this project intend to sequence the 50 most important cancers. In this work, the team led by López Otin and Field has used the most sophisticated technology, called 'Sidrón', to sequence the 3,000 million nucleotide complete genome of tumor cells in four patients. He then contrasted the results with the genome sequence of healthy cells from the same people.

With this operation found that each tumor has experienced a thousand mutations in their genome. And most importantly, have found that different patients are always the same mutations. Although this is a promising, is still far from implementing what has been achieved in clinical research field. According to Minister Cristina Garmendia, the Government will launch proceedings to Spanish companies to develop drugs that take advantage of discovery.

Garmendia pointed out that the sector companies will not be insensitive to "competitive advantage" that represents the finding in order to obtain new drugs. Chronic lymphocytic leukemia is the most common variant of leukemia in Western countries. It affects white blood cells responsible for the proper functioning of the immune system and usually appears after age 65, especially males.

Yesterday the Prime Minister, José Luis Rodríguez Zapatero, congratulated the researchers for their achievement is "an important international instrument in advancing the fight against cancer." In a telegram congratulates Zapatero researchers Elias Campo and Carlos Lopez-Otin, a congratulations to the director who joined Herminio Sastre.